Second CAR T–cell Therapy Approved by the FDA
Last week, the U.S. Food and Drug Administration (FDA) approved the second of a revolutionary new type of immunotherapy...
Category: Policy
Last week, the U.S. Food and Drug Administration (FDA) approved the second of a revolutionary new type of immunotherapy...
Scientific advancements are made through scientific research. From understanding the basic biology behind a disease to testing how well...
Last week, the U.S. Food and Drug Administration (FDA) provided some good news for the breast cancer community just...
Last week, the U.S. Food and Drug Administration (FDA) increased the number of types of cancer for which immunotherapeutics...
The flurry of treatments approved by the U.S. Food and Drug Administration (FDA) for treating hematological malignancies continued last...
Today, the American Association for Cancer Research (AACR) released its seventh annual Cancer Progress Report. The report highlights how...
This week’s excitement surrounding the groundbreaking U.S. Food and Drug Administration (FDA) approval of the CAR T–cell therapy tisagenlecleucel...
Yesterday marked a much anticipated milestone for the oncology community: The U.S. Food and Drug Administration (FDA) announced the...
Patient enrollment in clinical trials has long been on the minds of oncologists and researchers. In 1990, fewer than...
Earlier this week, the U.S. Food and Drug Administration (FDA) approved a new molecularly targeted therapeutic called neratinib (Nerlynx)...